APA (7th ed.) Citation

Damerow, H., Cheng, X., Kiedrowski, V. v., Schirrmacher, R., Wängler, B., Fricker, G., & Wängler, C. (2022). Toward optimized 89Zr-immuno-PET: Side-by-side comparison of (89Zr)Zr-DFO-, (89Zr)Zr-3,4,3-(LI-1,2-HOPO)- and (89Zr)Zr-DFO*-Cetuximab for tumor imaging : which chelator is the most suitable? Pharmaceutics, 14(10), . https://doi.org/10.3390/pharmaceutics14102114

Chicago Style (17th ed.) Citation

Damerow, Helen, Xia Cheng, Valeska von Kiedrowski, Ralf Schirrmacher, Björn Wängler, Gert Fricker, and Carmen Wängler. "Toward Optimized 89Zr-immuno-PET: Side-by-side Comparison of (89Zr)Zr-DFO-, (89Zr)Zr-3,4,3-(LI-1,2-HOPO)- and (89Zr)Zr-DFO*-Cetuximab for Tumor Imaging : Which Chelator Is the Most Suitable?" Pharmaceutics 14, no. 10 (2022). https://doi.org/10.3390/pharmaceutics14102114.

MLA (9th ed.) Citation

Damerow, Helen, et al. "Toward Optimized 89Zr-immuno-PET: Side-by-side Comparison of (89Zr)Zr-DFO-, (89Zr)Zr-3,4,3-(LI-1,2-HOPO)- and (89Zr)Zr-DFO*-Cetuximab for Tumor Imaging : Which Chelator Is the Most Suitable?" Pharmaceutics, vol. 14, no. 10, 2022, https://doi.org/10.3390/pharmaceutics14102114.